Magrolimab, a monoclonal antibody targeting CD47, is being evaluated for its safety and efficacy in treating hematological malignancies, specifically acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). The market for AML and MDS therapies is significant, with a growing demand for innovative treatments due to the high unmet need in relapsed/refractory cases. The discontinuation of this trial due to futility, based on the results of the ENHANCE trial, raises concerns about the competitive positioning of magrolimab against existing and emerging therapies in this space. The findings may impact Gilead Sciences' strategic direction and investment in CD47-targeting therapies.